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AT-1 receptor antagonism modifies the mediation of
endothelin-1, thromboxane A2, and catecholamines in the renal
constrictor response to angiotensin II.
Objective. The present study investigated the consequences
of partial AT1 receptor blockade on the participation of cate-
cholamines, thromboxane A2 (TXA2), and endothelin-1 (ET-1)
in the renal vasoconstriction induced by angiotensin II (Ang II).
Methods. For this purpose, the increase in renal perfusion
pressure (RPP) produced by Ang II was studied in isolated
kidneys from untreated or irbesartan-treated Wistar Kyoto and
spontaneously hypertensive rats (SHR), in absence or presence
of the alfa-1 receptor antagonist, prazosin, the TXA2 recep-
tor antagonist, ifetroban, or the ETA/ETB receptor antagonist,
PD145065.
Results. Systolic arterial pressure (SAP) was higher (P < 0.05)
in SHR than in WKY. Increases in RPP produced by Ang II were
comparable in kidneys from both untreated groups. Treatment
with irbesartan reduced SAP and RPP in both strains in a com-
parable extent. Presence of prazosin, ifetroban, or PD145065 in
perfusion media reduced (P < 0.05) Ang II maximal response in
all groups. Maximal inhibition of Ang II–induced vasoconstric-
tion produced by the 3 antagonists was comparable in untreated
WKY, but that of ifetroban and PD145065 was lower (P < 0.05)
than that of prazosin in untreated SHR. Maximal inhibition of
Ang II–induced vasoconstriction produced by the 3 antagonists
was comparable in WKY treated with irbesartan, and not dif-
ferent to that observed in untreated WKY. Maximal inhibitory
effect of the 3 antagonists was higher (P < 0.05) in treated than
in untreated SHR.
Conclusion. The study further supports the importance of
catecholamines, TXA2, and ET-1 as mediators of the renal
vasoconstriction induced by Ang II in both normotensive and
hypertensive rats. Hypertensive conditions appeared to re-
duce the participation of TXA2 and ET-1 in Ang II–induced
vasoconstriction when compared with normotensive conditions.
Chronic partial blockade of AT1 receptors did not affect the par-
ticipation of catecholamines, TXA2, and ET-1 in normotensive
rats, but increased the participation of the 3 mediators in SHR.
Key words: angiotensin II, kidney, hypertension, thromboxane A2,
endothelin-1, catecholamines, vasoconstriction, hypertension, an-
giotensin II blockade.
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This suggests that when AT1 receptors are partially blocked,
other vasoconstrictor factors could exert part of the renal vaso-
constrictor effects of Ang II.
Angiotensin II (Ang II) plays a key role in the reg-
ulation of renal function and arterial pressure, and has
been widely shown to participate in the renal functional
and structural complications of hypertension through a
variety of mechanisms [1–3]. Catecholamines, as well as
thromboxane A2 (TXA2) and endothelin-1 (ET-1), ex-
ert vascular renal and systemic actions similar to those of
Ang II, and participate in the vascular alterations asso-
ciated with hypertension [4–6]. Several studies reported
interactions among Ang II, catecholamines, ET-1, and
TXA2, which could be of importance for the regulation
of renal function under hypertensive conditions [7–10].
We previously observed that the AT1 receptor antagonist
losartan reduced constrictor responses to phenylephrine,
ET-1, and a TXA2 analog in aortic rings from sponta-
neously hypertensive rats (SHR), suggesting a media-
tory role of Ang II in the constrictor responses produced
by these endothelium-derived contracting factors [11].
In addition, other studies suggested that catecholamines,
TXA2, and ET-1 could mediate vascular actions of Ang II
under different experimental situations [7, 8, 10]. We al-
ready showed that TXA2 and ET-1 mediate the increase
in renovascular resistance produced by Ang II in isolated
kidneys from normotensive, hypertensive, and diabetic
rats [12]. In order to have a more in-depth understand-
ing of the interaction between Ang II, catecholamines,
TXA2, and ET-1, the present study investigated the con-
sequences of partial AT1 receptor blockade on the par-
ticipation of catecholamines, TXA2, and ET-1 in the
increase in renal vascular resistances (RVR) induced by
Ang II. This approach is based in the hypothesis that
partial AT1 receptor blockade would modify the medi-
ation of catecholamines, TXA2, and ET-1 in the renal
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Fig. 1. Concentration-dependent increases in renal perfusion pressure (RPP) produced by angiotensin II (Ang II) in isolated kidneys from WKY
and SHR, untreated and treated with irbesartan.
Table 1. Systolic arterial pressure (SAP), renal perfusion pressure
(RPP) in WKY and SHR, untreated and treated with irbesartan
WKY SHR WKY–IRB SHR–IRB
SAP mm Hg 131.0 ± 1.9 192.8 ± 3.9a 120.5 ± 2.4a 180.3 ± 2.3b
RPP mm 83.1 ± 3 86.5 ± 3 62.4 ± 6.4a 70.6 ± 6.3b
aP < 0.05 vs. WKY.
bP < 0.05 vs. SHR.
vasoconstriction induced by Ang II. For this purpose, the
increase in renal perfusion pressure (RPP) induced by
Ang II was studied in isolated kidneys from normotensive
and hypertensive rats, untreated and treated with irbesar-
tan, in absence and presence of the alfa-1 receptor antag-
onist prazosin, the TXA2 receptor antagonist ifetroban,
and the ETA/ETB receptor antagonist PD145065.
METHODS
Male adult (28-week-old) Wistar Kyoto rats (WKY)
(N = 32) and SHR (N = 32) (Charles River, Barcelona,
Spain) maintained under controlled light and tempera-
ture conditions were used in the study. Half of the an-
imals of each strain received a drinking solution of the
AT1 receptor antagonist irbesartan for 8 weeks, which
resulted in a dose of 10 mg/kg/day. The dose of irbesartan
was chosen in pilot studies to obtain a partial blockade
of Ang II–induced renal vasoconstriction. Animals had
free access to food (A.04; Panlab, Barcelona, Spain) and
either tap water or irbesartan solution. Systolic arterial
pressure (SAP) was estimated by a tail-cuff plethysmo-
graph (Narco Bio-Systems, Houston, TX, USA) as previ-
ously described [13]. The day of the experiment, animals
were anesthetized with sodium pentobarbital (50 mg/kg
IP); aorta was exposed by midline laparotomy and can-
nulated below the left kidney. Kidneys were perfused, re-
nal veins and ureters were cut, and then were placed in a
water-jacketed chamber maintained at 37◦C and perfused
at constant flow (4 mL/min) without recirculation by an
infusion pump (Harvard Apparatus, South Natick, MA,
USA) with oxygenated (95% O2/5% CO2) Krebs’s bicar-
bonate solution of the following composition (mmol/L):
NaCl 118.5, KCl 4.7, CaCl2 2.8, KH2PO4 1.1, NaHCO3
25.0, and glucose 11.1, at 37◦C. Perfusion pressure (PP)
was continuously monitored using a pressure transducer
(model P23XL; Spectromed, Cleveland, OH, USA), and
recorded on a polygraph (Model 7E; Grass Instruments,
Quincy, MA, USA). All experimental procedures were
approved by the institutional animal care and use com-
mittee according to the guidelines for ethical care of ex-
perimental animals of the European Union.
After 30 to 45 minutes equilibration period, kidneys
were contracted with 60 mmol/L KCl and these re-
sponses were used as references to express contractions to
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Fig. 2. Concentration-dependent reductions produced by the alfa-1 receptor antagonist prazosin on the increase in perfusion pressure produced
by angiotensin II (10−5 mol/L) in isolated kidneys from WKY and SHR, untreated and treated with irbesartan.
Ang II. Dose-related contracting responses induced by
Ang II (10−8 to 10−5 mol/L) were evaluated in all ani-
mals. Afterwards, the response to Ang II (10−5 mol/L)
in presence of the alfa-1 receptor antagonist prazosin
(10−9 to 10−5 mol/L), the TXA2/PGH2 receptor antag-
onist, ifetroban (10−8 to 10−4 mol/L), or the ETA/ETB
receptor antagonist, PD145065 (10−8 to 10−4 mol/L), was
assayed in kidneys from each group. Since the perfusion
rate was constant throughout the experimental period,
variations of perfusion pressure (PP) were indicative of
changes in renal vascular resistance (RVR). Changes in
renal PP were calculated by subtracting the value of PP
obtained just before the Ang II injection from the value
of PP measured at the time of maximal effect.
All drugs and chemicals were purchased from Sigma
Chemical Co., St. Louis, MO, USA. Stock solutions of
drugs were prepared in distilled water and diluted to the
desired concentration with Kreb’s solution immediately
before the experiment. Results are expressed as mean ±
SEM of at least 8 experiments. Dose-response curves
were compared by multivariate analysis of variance for
repeated measures (MANOVA) using the STATISTICA
program (Statsoft, Inc., Tulsa, OK, USA). All other
data were analyzed using a one-way analysis of variance
(ANOVA), followed by a Newman-Keuls test if differ-
ences were noted. The null hypothesis was rejected when
the P value was less than 0.05.
RESULTS
As shown in Table 1, SAP levels were higher (P < 0.05)
in SHR than in WKY. However, basal RPP was compara-
ble in untreated WKY and SHR. Treatment with irbesar-
tan reduced SAP and RPP in both strains in a comparable
extent (Table 1).
Untreated rats
Increases in RPP produced by KCl were similar in kid-
neys from all groups (data not shown). Dose-dependent
increases in RPP produced by Ang II were comparable
in kidneys from both untreated groups (Fig. 1). Presence
of prazosin, ifetroban, or PD145065 in perfusion media
reduced (P < 0.05) Ang II maximal response in both
strains in a differential manner (Figs. 2 to 4). This in-
hibitory effect occurred at lower concentrations of pra-
zosin and ifetroban than with PD145065 in both strains
(Figs. 2 to 4). Maximal inhibition of Ang II–induced
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Fig. 3. Concentration-dependent reductions produced by the TXA2/PGH2 receptor antagonist ifetroban on the increase in perfusion pressure
produced by angiotensin II (10−5 mol/L) in isolated kidneys from WKY and SHR, untreated and treated with irbesartan.
vasoconstriction produced by the 3 antagonists was com-
parable in WKY. However, maximal inhibitory effect of
prazosin was higher (P < 0.05) than that of ifetroban and
PD145065 in SHR (Table 2).
Irbesartan-treated rats
As expected, increase in RPP produced by Ang II was
lower (P < 0.05) in rats treated with irbesartan than in
untreated animals from each strain (Fig. 1). No differ-
ences were observed in the response to Ang II between
both treated groups. Presence of prazosin, ifetroban, or
PD145065 in perfusion media reduced (P < 0.05) Ang II
maximal response in both strains in a differential manner
(Figs. 2 to 4). This inhibitory effect occurred at lower con-
centrations of prazosin and ifetroban than with PD145065
in both strains (Figs. 2 to 4). Maximal inhibition of
Ang II–induced vasoconstriction produced by the 3 an-
tagonists was comparable in treated WKY and not differ-
ent to that observed in untreated WKY (Table 2). Maxi-
mal inhibitory effect of the 3 antagonists was higher (P <
0.05) in irbesartan-treated SHR than in untreated SHR
(Table 2).
DISCUSSION
The present study further supports the mediatory role
of catecholamines, TXA2, and ET-1 in the renal vaso-
constriction induced by Ang II in both normotensive
and hypertensive rats. Hypertension did not affect the
participation of alfa-1 receptors in the increase in RPP
produced by Ang II, but reduced the participation of
TXA2 and ET-1 compared to normotensive rats. Partial
AT1 receptor blockade with irbesartan increased the par-
ticipation of the 3 mediators only in hypertensive rats,
suggesting a certain rearrangement of the factors medi-
ating Ang II renal vasoconstriction under hypertensive
conditions.
Increase in RPP produced by Ang II was comparable
in both WKY and SHR, indicating that basal renal vas-
cular tone, as well as the increase in RVR produced by
Ang II, is not altered in established hypertension. These
results are in agreement with those reported for adult
SHR, and contrast with those found in young SHR, where
the renal response to Ang II was higher than in normoten-
sive rats [14–17]. The enhanced renal responsiveness to
Ang II and other vasoconstrictors has been proposed
to be an important determinant of the development of
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Fig. 4. Concentration-dependent reductions produced by the ETA/ETB receptor antagonist PD145065 on the increase in perfusion pressure
produced by angiotensin II (10−5 mol/L) in isolated kidneys from WKY and SHR, untreated and treated with irbesartan.
hypertension in SHR. However, the alterations in renal
hemodynamics and function become less pronounced as
the hypertension advances to an established phase in
SHR [18]. Consequently, it appears that once hyperten-
sion is established, enhanced renal responses to vasocon-
strictor agents are normalized.
The results further support the notion that cate-
cholamines, TXA2, and ET-1 partially mediate renal
vasoconstriction produced by Ang II in both normoten-
sive and hypertensive rats, as demonstrated by the reduc-
tion in Ang II–induced contracting responses observed in
presence of ifetroban or PD145065 [12]. This inhibitory
effect occurred at lower concentrations of prazosin and
ifetroban than those of PD145065 in both strains, sug-
gesting a greater sensitivity of Ang II response to alfa-1
and PGH2/TXA2 receptor blockade than to ETA/ETB
receptor blockade. However, maximal inhibition of Ang
II–induced vasoconstriction produced by the 3 antago-
nists was comparable in untreated WKY, probably sug-
gesting a comparable net participation of the 3 constrictor
factors in the renal vasoconstriction produced by Ang II
in normotensive animals. In contrast, it appears that ac-
tivation of TXA2 and ET-1 receptors play a lesser role
mediating Ang II vasoconstriction in SHR than in WKY,
as suggested by the lower reduction of Ang II constriction
produced by ifetroban and PD145065. The relevance of
catecholamines in renovascular resistances in hyperten-
sive models has been shown in previous studies [19–21].
The present study further supports this concept, and em-
phasizes that this predominant role also affects Ang II–
induced vasoconstriction [12].
The mechanisms responsible for the reduction in Ang
II–induced vasoconstriction observed in the presence of
each of the 3 inhibitors used is not clear. It has been
proposed that catecholamines, TXA2, and ET-1 could
act as amplifiers of the constrictor response to Ang II
[22]. This effect seems to depend on the stimulation of
Ang II on catecholamines, TXA2, and ET-1 synthesis
and release [23–26]. Furthermore, it could also be due to
the existence of a cross-talk between receptors for these
vasoconstrictor factors, which could be related with the
common intracellular signaling pathways that they share.
This hypothesis is supported by the demonstration that
Ang II, catecholamines, TXA2, and ET-1 bind to spe-
cific G protein–coupled receptors, which stimulate PKC
and other intracellular signal pathways, leading to the
increase of calcium concentration and subsequent vaso-
constriction [27–29].
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Table 2. Maximal inhibition (%) of Ang II renal contraction in WKY
and SHR, untreated and treated with irbesartan
WKY SHR WKY+IRB SHR+IRB
Prazosin 52.1 ± 5.1 51.2 ± 2.9 50.6 ± 4.5 70.7 ± 6.1b
Ifetroban 51.3 ± 4.3 37.1 ± 2.1a 49.3 ± 3.1 79.4 ± 5.4b
PD 145 53.6 ± 5.7 33.6 ± 2.4a 52.6 ± 4.2 64.7 ± 6.2b
aP < 0.05 vs. Prazosin SHR.
bP < 0.05 vs. respective prazosin, ifetroban, PD 145 SHR group.
Prolonged administration of irbesartan did not change
the maximal inhibition produced by the 3 inhibitors
on the Ang II renal vasoconstriction in normotensive
rats when compared to untreated animals. In contrast,
blockade of AT1 receptors increased maximal inhibition
caused by the 3 inhibitors in SHR. This indicates that
during of AT1 receptor blockade, an enhancement of the
participation of catecholamines, TXA2, and ET-1 in Ang
II–induced renal vasoconstriction occurred only in hyper-
tensive conditions, probably as a compensatory mecha-
nism. Although the study does not allow us to define the
mechanisms accounting for different responses of WKY
and SHR to irbesartan treatment, a hemodynamic effect
depending on the antihypertensive and vasodilatory ef-
fects of irbesartan can be ruled out, because the drug
reduced SAP and RPP in a similar extent in both strains.
Finally, the results also suggest that when AT1 receptors
are partially blocked, catecholamines, TXA2, and ET-1
could exert part of the vasoconstrictor effects of Ang II.
Similar to that discussed above, this effect could depend
on the stimulation of Ang II on catecholamines, TXA2,
and ET-1 synthesis and release, and/or to the common
intracellular signaling pathways shared by these vasocon-
strictor agents [22–29].
CONCLUSION
The present study further supports the importance of
catecholamines, TXA2, and ET-1 as mediators of the re-
nal vasoconstriction induced by Ang II in both normoten-
sive and hypertensive rats. Hypertensive conditions
appeared to reduce the participation of TXA2 and ET-1
in Ang II–induced vasoconstriction when compared with
normotensive conditions. Chronic partial blockade of
AT1 receptors did not affect the participation of cate-
cholamines, TXA2, and ET-1 in normotensive rats, but in-
creased the participation of the 3 mediators in SHR. This
suggests that when AT1 receptors are partially blocked,
other vasoconstrictor factors could exert part of the renal
vasoconstrictor effects of Ang II.
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